The NeoChord Artificial Chordae Delivery System is a beating heart procedure, echo-guided treatment option for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. LEARN MORE ABOUT …
Show more
See More
NeoChord ConsultConnect and ConnectCARD is a medical consultation and service related to delivery of artificial chordae tendineae for treatment of mitral insufficiency.The NeoChord Artificial Chordae Delivery System, Model DS1000, meets the essential requirements referred to in Article 3 of the MDD 93/42/EEC and is labeled with the CE marking of conformity.
Show more
See More
In general, loop sizes fall within the following ranges in most patients: PML 10-16 mm; AML 20-26 mm; and commissures 16-20 mm. AML ¼ anterior mitral leaflet; MR ¼ mitral regurgitation; PML ¼ posterior mitral leaflet. Myxomatous mitral valve repair by loop NeoChord technique 113. Loops for NeoChordae.
Show more
See More
Aug 14, 2018 . The NeoChord device, in illustration, is inserted in the beating heart through a small incision, guided by echocardiography “While the heart is beating, you make a small incision under the patient’s left nipple, insert the device, and implant the artificial chords to the mitral valve,” says Dr. El-Eshmawi, the site Principal Investigator for the study.
Show more
See More
Jun 17, 2016 . Inclusion Criteria: Is a candidate for mitral valve repair with cardiopulmonary bypass. Has Grade III moderate or Grade IV severe degenerative mitral valve regurgitation. Primary segmental prolapse of the A2 or P2 segment or prolapse extending to an adjacent segment (P1, P3, A1, A3) who have a single eccentric regurgitant jet on echocardiogram.
Allocation: Randomized
Intervention Model: Parallel Assignment
Estimated Enrollment : 585 participants
Study Type : Interventional (Clinical Trial)
Show more
See More
Jan 08, 2013 . Tech Update: NeoChord Mitral Valve Repair Device Gets CE Mark. By Adam Pick on January 8, 2013. As we continue to monitor the newest technologies enhancing valvular therapy, I though you might like to know that the NeoChord mitral valve repair system recently received a CE mark for use in Europe. This unique device, which is not FDA approved in ...
Show more
See More
NeoChord is a privately held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company’s flagship product, the NeoChord Artificial Chordae Delivery System, received CE market clearance in December 2012.
Show more
See More
NeoChord Announces Positive 30-day Results with Transcatheter NeXuS System for Mitral Chordal Repair Using Multiple Chords to a Single Anchor. ST. LOUIS PARK, Minn., Nov. 22, 2021 (GLOBE NEWSWIRE ...
Show more
See More
NeoChord NeXuS is an investigational device and is not commercially available. Contact Jenny Donovan NeoChord, Inc. (952) 698-7809 jdonovan@NeoChord.com ...
Show more
See More
All English articles on humans reporting isolated MVr using NeoChord DS1000 device were included provided that basic preoperative data, operative specifications, and postoperative mortality and morbidity were reported. Results. This review included six studies comprised 249 patients who had NeoChord mitral procedure.
Publish Year: 2021
Author: Ahmed Ahmed, Tarek A. Abdel‐Aziz, Mohannad M. R. AlAsaad, Motaz Majthoob
Show more
See More
Digital animation of beating-heart, sternal-sparing implantation of artificial chordae tendineae enabled by NeoChord's surgical device -- a minimally-invasiv...
Show more
See More
NeoChord is a privately held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. NeoChord ConsultConnect and ConnectCARD is a medical consultation and service related to delivery of artificial chordae tendineae for treatment of mitral insufficiency.
specs
Show more
See More
Jan 29, 2013 . Safety and Performance Study of the NeoChord Device (TACT) The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Show more
See More
NeoChord Device Patent NeoChord, Inc. has a pending patent (US 2009/0105751) for a device designed to perform minimally invasive repair of a valve leaflet in a beating heart. The NeoChord device, invented by John Zentgraf, is an existing solution to deliver and implant artificial chordae tendineae to the mitral valve leaflet and is likely the most promising current solution.
Show more
See More
Oct 28, 2016 . NeoChord Again Awarded NUB Status 1 In Germany. 2/10/2016. NeoChord Appoints Lori Adels, Ph.D. As Vice President Of Clinical Affairs, Regulatory And Quality. 10/20/2015. NeoChord Bags $12.6 Million for Mitral Valve Repair Tool That Works Without Stopping the Heart. 5/26/2015. NeoChord Appoints David Chung As President And CEO. …
specs
Show more
See More
The NeoChord DS1000 is a disposable device that is intended to replace damaged chordae by delivering artifical chordae tendinae or "NeoChords" in a beating heart using minimally invasive techniques. In patients with severe degenerative mitral valve regurgitation, early surgery is recommended for patients with no symptoms because the probability of surgical success is high.
Show more
See More
The NeoChord undergoes a series of changes with time as the microporous structure fills with blood components with subsequent organization. These provide a possible nidus for dystrophic calcification as shown in this case that ultimately can lead to stiffening, and stress failure of the NeoChord. Although no infection could be detected, the ...
specs
Show more
See More
The NeoChord DS1000 (A) has the following features: A tip with expandable jaws to grasp the leaflet and 4 fiber-optic channels (B) each of which corresponds to …
Show more
See More
NeoChord is a privately held medical technology company leading the advancement of beating heart mitral valve repair in patients suffering from mitral valve regurgitation. The company’s flagship product, the NeoChord Artificial Chordae Delivery System, received CE market clearance in December 2012.
The NeoChord Artificial Chordae Delivery System is a beating heart procedure, echo-guided treatment option for patients with mitral valve regurgitation and is proven to resolve and restore normal mitral valve function. This opens in a new window.
A clinical study is ongoing within the United States to evaluate the use of the NeoChord DS1000. Mount Sinai Heart is leading a multicenter clinical trial of a minimally invasive mitral valve prolapse repair technology that has the potential to transform the standard of care for the disorder.
Tech Update: NeoChord Mitral Valve Repair Device Gets CE Mark. This unique device, which is not FDA approved in America, enables minimally invasive implantation of artificial chordae using a catheter-based approach. If you did not know, the chordae support the mitral valve leaflets as they open-and-close to move the blood through your heart.